Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Exelixis
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07620574CT.gov Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | — | Not Yet Recruiting | — | — | — |
NCT06811116CT.gov Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial | — | Recruiting | — | — | — |
NCT07151326CT.gov Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy | — | Not Yet Recruiting | — | — | — |
NCT06535737CT.gov A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab | — | Not Yet Recruiting | — | — | — |
NCT05797805CT.gov A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05039736CT.gov A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy | — | Withdrawn | — | — | — |
NCT05327738CT.gov Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT05168163CT.gov Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | — | Recruiting | — | — | — |
NCT05092373CT.gov Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | — | Recruiting | — | — | — |
NCT04767906CT.gov Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors | — | Completed | — | — | — |
Show 20 more trialsShow fewer
NCT05100082CT.gov Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04442581CT.gov Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | — | Terminated | — | — | — |
NCT04511455CT.gov Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment | — | Completed | — | — | — |
NCT04588051CT.gov Cabozantinib in Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04522908CT.gov Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function | — | Completed | — | — | — |
NCT04472767CT.gov Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04204850CT.gov Cabozantinib to Treat Recurrent Liver Cancer Post Transplant | — | Recruiting | — | — | — |
NCT04316182CT.gov Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION) | — | Completed | — | — | — |
NCT04454762CT.gov A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function | — | Unknown | — | — | — |
NCT04435977CT.gov Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03963206CT.gov Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) | — | Completed | — | — | — |
NCT03899428CT.gov Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC | — | Recruiting | — | — | — |
NCT03539822CT.gov Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies | — | Recruiting | — | — | — |
NCT03586973CT.gov A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT03755791CT.gov Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy | — | Active Not Recruiting | — | — | — |
NCT03299946CT.gov Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT03170960CT.gov Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02867592CT.gov Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | — | Active Not Recruiting | — | — | — |
NCT01908426CT.gov Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | — | Completed | — | — | — |
NCT01658878CT.gov An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cabozantinib (this asset) | Exelixis | Approved | BB · 66 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Cabozantinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BB · 70 |
| Castration-Resistant Prostate Carcinoma | — | P3 | BB · 70 |
| Kidney Cancer | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cabozantinib in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cabozantinib-hepatocellular-carcinoma-10139
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →